PMID- 10532605
OWN - NLM
STAT- MEDLINE
DCOM- 19991102
LR  - 20190727
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 39
IP  - 10
DP  - 1999 Oct
TI  - Efficacy of donor screening for HTLV-I and the natural history of 
      transfusion-transmitted infection.
PG  - 1104-10
AB  - BACKGROUND: It has been 10 years since the implementation in Japan of donor blood 
      screening for human T-cell lymphotropic virus type I (HTLV-I). This report 
      reviews the effectiveness of screening in preventing transmission of HTLV-I 
      through blood transfusion and the current status of patients with confirmed 
      seroconversion due to transfusions given before the implementation of screening. 
      STUDY DESIGN AND METHODS: Patients who received blood at Kyushu University 
      Hospital from 1990 to 1997 were followed. Serum samples were collected before 
      transfusion and 60 days or more after transfusion. Seroconversion was determined 
      by a second-generation particle agglutination test. Confirmation tests were an 
      immunofluorescence assay, enzyme-linked immunosorbent assay, and immunoblotting. 
      Confirmed seroconverted patients were followed by a search of hospital records. 
      RESULTS: Seroconversion was found in one of 4672 transfused patients, but the 
      donor was identified and confirmed to be negative for anti-HTLV-I and virus 
      genome by nested polymerase chain reaction. A total of 23,323 red cell 
      concentrates and 17,237 platelet concentrates were transfused to these 4672 
      patients. Therefore, the anti-HTLV-I prevalence in blood for transfusion after 
      screening was estimated at 1 in 45,560 (0.0022%; the upper 95% CI was 0.0080%). 
      One hundred two seroconverted patients who were transfused before donor screening 
      for HTLV-I were followed. One patient developed HTLV-I-associated myelopathy, 
      diagnosed 18 weeks after seroconversion, and another patient developed uveitis 1 
      month after seroconversion. No patients developed adult T-cell lymphoma, and the 
      survival rate of seroconverted patients was 92.5 percent 15 years after 
      transfusion. CONCLUSION: This study confirmed that the present donor screening 
      program for HTLV-I by the new particle agglutination test can almost completely 
      prevent virus transmission by transfusion. Complications of HTLV-I transmission 
      were at lower rates than expected.
FAU - Inaba, S
AU  - Inaba S
AD  - Blood Transfusion Service, Kyushu University Hospital, Fukuoka, Japan. 
      shotyan@transf.med.kyushu-u.ac.jp
FAU - Okochi, K
AU  - Okochi K
FAU - Sato, H
AU  - Sato H
FAU - Fukada, K
AU  - Fukada K
FAU - Kinukawa, N
AU  - Kinukawa N
FAU - Nakata, H
AU  - Nakata H
FAU - Kinjyo, K
AU  - Kinjyo K
FAU - Fujii, F
AU  - Fujii F
FAU - Maeda, Y
AU  - Maeda Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Agglutination Tests
MH  - *Blood Donors
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - HTLV-I Infections/*diagnosis/physiopathology/*transmission
MH  - Humans
MH  - Infant
MH  - Male
MH  - *Mass Screening
MH  - Middle Aged
MH  - Paraparesis, Tropical Spastic/etiology
MH  - Serologic Tests
MH  - Survival Analysis
MH  - *Transfusion Reaction
MH  - Uveitis/virology
EDAT- 1999/10/26 00:00
MHDA- 1999/10/26 00:01
CRDT- 1999/10/26 00:00
PHST- 1999/10/26 00:00 [pubmed]
PHST- 1999/10/26 00:01 [medline]
PHST- 1999/10/26 00:00 [entrez]
AID - 10.1046/j.1537-2995.1999.39101104.x [doi]
PST - ppublish
SO  - Transfusion. 1999 Oct;39(10):1104-10. doi: 10.1046/j.1537-2995.1999.39101104.x.